Antibodies are tremendously useful and versatile tools and they have found use in many areas of life science research. However, antibodies can be difficult to make and are used in inherently complex biological systems. Consequently, they can be prone to quality issues: batch-to-batch variability, lack of specificity, or poor sensitivity. The impact of this can be substantial, both financially and scientifically as identified in recent studies.
Learn how at Abcam, we are raising industry quality standards by using newer and improved technology to manufacture and validate our products. Addressing both specificity and reproducibility issues, we have recently introduced knockout (KO) validation at scale. Utilizing human *KO cell lines generated from haploid cellular models using CRISPR/Cas9, the technology has enabled the development of a growing range of KO validated antibodies, including many recombinant monoclonals.
This webinar will review:
Learning objectives:
*Abcam validates antibodies using KO cell lines from Horizon Discovery
Introducing knockout validation | Abcam’s standard quality control protocol for antibodies
The technology behind knockout cell lines | Human knockout cell lines using CRISPR/Cas9 genome-editing
Knockout validation results | See the different scenario of results and what it means for you
Why use recombinant antibodies? | Highly reproducible with tailored specificity
The benefits of RabMAb® recombinant antibodies | Combining the unique advantages of the rabbit immune system and recombinant technology